A case of anaphylaxis to Pollinex® Quattro MPL-4.
We described the first case reported in literature of anaphylactic shock after administration of pollen extract vaccine chemically modified (allergoid) adsorbed onto L-Tyrosine depot adjuvanted with monophosphoryl lipid A (Pollinex® Quattro MPL-4).
Allergy and Clinical Immunology Unit, H. "L. Sacco" Milano, Italy. allergoimmuno@hsacco.it.
L
L
Borgonovo
Allergy and Clinical Immunology Unit, H. "L. Sacco" Milano, Italy.
S
S
Piconi
Allergy and Clinical Immunology Unit, H. "L. Sacco" Milano, Italy.
A
A
Fusi
Allergy and Clinical Immunology Unit, H. "L. Sacco" Milano, Italy.
E
E
Iemoli
D000707:Anaphylaxis / Q000139:chemically induced*; D006801:Humans; D008050:Lipid A / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D014612:Vaccines / Q000009:adverse effects*
D008050:Lipid A; C516537:Pollinex Quattro; D014612:Vaccines; C048436:monophosphoryl lipid A
Anaphylaxis; allergoid; monophosphoryl lipid A; subcutaneous allergen immunotherapy (SCIT)